State Street’s Actinium Pharmaceuticals ATNM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $126K | Hold |
126,215
| – | – | ﹤0.01% | 3987 |
|
|
2025
Q4 | $172K | Hold |
126,215
| – | – | ﹤0.01% | 3931 |
|
|
2025
Q3 | $202K | Sell |
126,215
-95,800
| -43% | -$156K | ﹤0.01% | 3916 |
|
|
2025
Q2 | $311K | Sell |
222,015
-423,200
| -66% | -$633K | ﹤0.01% | 3723 |
|
|
2025
Q1 | $1.04M | Buy |
645,215
+24,140
| +4% | +$30.6K | ﹤0.01% | 3418 |
|
|
2024
Q4 | $783K | Buy |
621,075
+18,426
| +3% | +$28.6K | ﹤0.01% | 3536 |
|
|
2024
Q3 | $1.13M | Sell |
602,649
-7,024
| -1% | -$27.8K | ﹤0.01% | 3465 |
|
|
2024
Q2 | $4.51M | Buy |
609,673
+58,828
| +11% | +$484K | ﹤0.01% | 2972 |
|
|
2024
Q1 | $4.31M | Buy |
550,845
+44,003
| +9% | +$283K | ﹤0.01% | 2991 |
|
|
2023
Q4 | $2.57M | Sell |
506,842
-16,150
| -3% | -$83.2K | ﹤0.01% | 3229 |
|
|
2023
Q3 | $3.1M | Buy |
522,992
+41,289
| +9% | +$275K | ﹤0.01% | 3143 |
|
|
2023
Q2 | $3.57M | Buy |
481,703
+385,688
| +402% | +$3.28M | ﹤0.01% | 3164 |
|
|
2023
Q1 | $907K | Buy |
96,015
+7,700
| +9% | +$81.3K | ﹤0.01% | 3560 |
|
|
2022
Q4 | $941K | Buy |
88,315
+13,100
| +17% | +$133K | ﹤0.01% | 3576 |
|
|
2022
Q3 | $555K | Hold |
75,215
| – | – | ﹤0.01% | 3739 |
|
|
2022
Q2 | $362K | Buy |
75,215
+12,200
| +19% | +$69.3K | ﹤0.01% | 3966 |
|
|
2022
Q1 | $322K | Buy |
63,015
+7,023
| +13% | +$37K | ﹤0.01% | 4213 |
|
|
2021
Q4 | $337K | Buy |
55,992
+700
| +1% | +$5.25K | ﹤0.01% | 4149 |
|
|
2021
Q3 | $490K | Hold |
55,292
| – | – | ﹤0.01% | 3986 |
|
|
2021
Q2 | $437K | Buy |
+55,292
| New | +$434K | ﹤0.01% | 3906 |
|
|
2018
Q3 | – | Sell |
-390
| Closed | -$8K | – | 3772 |
|
|
2018
Q2 | $8K | Hold |
390
| – | – | ﹤0.01% | 3758 |
|
|
2018
Q1 | $4K | Hold |
390
| – | – | ﹤0.01% | 3748 |
|
|
2017
Q4 | $8K | Hold |
390
| – | – | ﹤0.01% | 3718 |
|
|
2017
Q3 | $7K | Hold |
390
| – | – | ﹤0.01% | 3752 |
|
|
2017
Q2 | $14K | Hold |
390
| – | – | ﹤0.01% | 3666 |
|
|
2017
Q1 | $17K | Hold |
390
| – | – | ﹤0.01% | 3625 |
|
|
2016
Q4 | $11K | Hold |
390
| – | – | ﹤0.01% | 3638 |
|
|
2016
Q3 | $16K | Hold |
390
| – | – | ﹤0.01% | 3543 |
|
|
2016
Q2 | $21K | Hold |
390
| – | – | ﹤0.01% | 3653 |
|
|
2016
Q1 | $24K | Hold |
390
| – | – | ﹤0.01% | 3658 |
|
|
2015
Q4 | $38K | Hold |
390
| – | – | ﹤0.01% | 3622 |
|
|
2015
Q3 | $21K | Hold |
390
| – | – | ﹤0.01% | 3652 |
|
|
2015
Q2 | $31K | Sell |
390
-9,005
| -96% | -$769K | ﹤0.01% | 3637 |
|
|
2015
Q1 | $695K | Buy |
9,395
+2,234
| +31% | +$266K | ﹤0.01% | 3303 |
|
|
2014
Q4 | $1.26M | Buy |
7,161
+246
| +4% | +$46.7K | ﹤0.01% | 3207 |
|
|
2014
Q3 | $1.39M | Buy |
6,915
+789
| +13% | +$156K | ﹤0.01% | 3159 |
|
|
2014
Q2 | $1.33M | Buy |
+6,126
| New | +$2.04M | ﹤0.01% | 3186 |
|
Other funds holding ATNM
VCM
GS
VFT
State Street's ATNM Position: Q1 2026 in Review
State Street held its Actinium Pharmaceuticals (ATNM) position steady in Q1 2026 at 126,215 shares worth $126K. The position accounts for ﹤0.01% of the portfolio, ranked #3987.
State Street first reported a position in ATNM in Q2 2014 and has held it in 37 quarters since. The position peaked at $4.51M in Q2 2024. 54 funds tracked by Wall St. Rank hold ATNM as of Q1 2026.
- State Street held 126,215 shares of Actinium Pharmaceuticals worth $126K as of Q1 2026.
- State Street left its Actinium Pharmaceuticals share count unchanged in Q1 2026.
- Actinium Pharmaceuticals made up ﹤0.01% of State Street's portfolio in Q1 2026, its #3987 holding.
- State Street first reported a position in Actinium Pharmaceuticals in Q2 2014 and has held it in 37 quarters since.
- State Street's Actinium Pharmaceuticals position peaked at $4.51M in Q2 2024.
- 54 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q1 2026.
Based on State Street's 13F filing for Q1 2026, filed 15 May 2026.